Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (64 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 20 | 0.70 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6401
Sealed predictions
- SYNGR3 in dopamine neurons, braak-0.65 (p 0.058) → +0.38 (p 0.309)receipt 6408
Swarm cases
receipt 6408: SYNGR3 in dopamine neurons, braak
- power
- full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.555, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.19 (p 0.444, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.01, sign flips 1; without severely affected donors -0.12 (p 0.640, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SYNGR3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts